Increased serum interleukin-31 levels correlate with pruritus in psoriatic patients: a cross-sectional study in Vietnam
https://doi.org/10.4081/dr.2024.10090
Accepted: 24 November 2024
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Psoriasis is recognized not only as a skin disease but also as a systemic disorder. Interleukin-31 (IL-31) may be associated with psoriasis and systemic inflammation. We aimed to quantify serum IL-31 levels in patients with psoriasis and explore their associations with specific clinical manifestations. 30 patients with psoriasis and 30 healthy controls were included in this study. Demographic information and clinical characteristics were obtained through physical examination and medical history review. Serum IL-31 levels were measured using an enzyme-linked immunosorbent assay. IL-31 concentration was significantly higher in patients with psoriasis than in the control group (p<0.001). Patients with psoriasis vulgaris, psoriasis erythroderma, and pustular psoriasis had significantly higher serum IL-31 levels than healthy controls. Additionally, serum IL-31 levels were associated with itch numerical rating scale (NRS) scores and body mass index (BMI) but not with disease severity as measured by the Psoriasis Area and Severity Index (PASI). In patients with psoriasis, increased serum IL-31 levels correlated with itch severity but not with PASI. This suggests that IL-31 may play a critical role in the pathogenesis of psoriasis and could be a valuable target for further studies and therapeutic interventions.
Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet 2021;397:1301-15. DOI: https://doi.org/10.1016/S0140-6736(20)32549-6
Elewski B, Alexis AF, Lebwohl M, et al. Itch: an under-recognized problem in psoriasis. J Eur Acad Dermatol Venereol 2019;33:1465-76. DOI: https://doi.org/10.1111/jdv.15450
Narbutt J, Olejniczak I, Sobolewska-Sztychny D, et al. Narrow band ultraviolet B irradiations cause alteration in interleukin-31 serum level in psoriatic patients. Arch Dermatol Res 2013;305:191-5. DOI: https://doi.org/10.1007/s00403-012-1293-6
Bautista-Herrera LA, De la Cruz-Mosso U, Román-Fernández IV, et al. A potential inflammatory role of IL-31 in psoriatic arthritis: A correlation with Th17 cytokine profile. Int J Immunopathol Pharmacol 2020;34:2058738420907186. DOI: https://doi.org/10.1177/2058738420907186
Chaowattanapanit S, Choonhakarn C, Salao K, et al. Increased serum IL-31 levels in chronic spontaneous urticaria and psoriasis with pruritic symptoms. Heliyon 2020;6:e05621. DOI: https://doi.org/10.1016/j.heliyon.2020.e05621
Conrad C, Gilliet M. Psoriasis: from Pathogenesis to Targeted Therapies. Clinical reviews in allergy & immunology 2018;54:102-13. DOI: https://doi.org/10.1007/s12016-018-8668-1
Price A and Cohen DE. Assessment of pruritus in patients with psoriasis and atopic dermatitis: subjective and objective tools. Dermatitis 2014;25:334-44. DOI: https://doi.org/10.1097/DER.0000000000000077
Kimball AB, Naegeli AN, Edson-Heredia E, et al. Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to severe plaque psoriasis. Br J Dermatol 2016;175:157-62. DOI: https://doi.org/10.1111/bjd.14464
Phan NQ, Blome C, Fritz F, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol 2012;92:502-7. DOI: https://doi.org/10.2340/00015555-1246
Reich A, Heisig M, Phan NQ, et al. Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol 2012;92:497-501. DOI: https://doi.org/10.2340/00015555-1265
Komiya E, Tominaga M, Kamata Y, et al. Molecular and Cellular Mechanisms of Itch in Psoriasis. Int J Mol Sci 2020;21 DOI: https://doi.org/10.3390/ijms21218406
Ferretti E, Corcione A and Pistoia V. The IL-31/IL-31 receptor axis: general features and role in tumor microenvironment. J Leukoc Biol 2017;102:711-7. DOI: https://doi.org/10.1189/jlb.3MR0117-033R
Edukulla R, Singh B, Jegga AG, et al. Th2 Cytokines Augment IL-31/IL-31RA Interactions via STAT6-dependent IL-31RA Expression. J Biol Chem 2015;290:13510-20. DOI: https://doi.org/10.1074/jbc.M114.622126
Niyonsaba F, Ushio H, Hara M, et al. Antimicrobial peptides human beta-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells. J Immunol 2010;184:3526-34. DOI: https://doi.org/10.4049/jimmunol.0900712
Di Salvo E, Ventura-Spagnolo E, Casciaro M, et al. IL-33/IL-31 Axis: A Potential Inflammatory Pathway. Mediators Inflamm 2018;2018:3858032. DOI: https://doi.org/10.1155/2018/3858032
Bağci IS and Ruzicka T. IL-31: A new key player in dermatology and beyond. J Allergy Clin Immunol 2018;141:858-66. DOI: https://doi.org/10.1016/j.jaci.2017.10.045
Rosine N, Etcheto A, Hendel-Chavez H, et al. Increase In Il-31 Serum Levels Is Associated With Reduced Structural Damage In Early Axial Spondyloarthritis. Sci Rep 2018;8:7731. DOI: https://doi.org/10.1038/s41598-018-25722-z
Bilsborough J, Leung DY, Maurer M, et al. IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. J Allergy Clin Immunol 2006;117:418-25. DOI: https://doi.org/10.1016/j.jaci.2005.10.046
Szepietowski JC, Reich A and Wisnicka B. Pruritus and psoriasis. Br J Dermatol 2004;151:1284. DOI: https://doi.org/10.1111/j.1365-2133.2004.06299.x
Reich A and Szepietowski JC. Mediators of pruritus in psoriasis. Mediators Inflamm 2007;2007:64727. DOI: https://doi.org/10.1155/2007/64727
Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006;117:411-7. DOI: https://doi.org/10.1016/j.jaci.2005.10.033
Wongjirattikarn R, Chaisuriya N, Chaowattanapanit S, et al. Increased tissue expression of IL-31 in patients with psoriasis. Cytokine 2024;176:156531. DOI: https://doi.org/10.1016/j.cyto.2024.156531
Sampogna F, Gisondi P, Melchi CF, et al. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol 2004;151:594-9. DOI: https://doi.org/10.1111/j.1365-2133.2004.06093.x
Théréné C, Brenaut E, Barnetche T, et al. Efficacy of Systemic Treatments of Psoriasis on Pruritus: A Systemic Literature Review and Meta-Analysis. J Invest Dermatol 2018;138:38-45. DOI: https://doi.org/10.1016/j.jid.2017.05.039
Farber EM, Nickoloff BJ, Recht B, et al. Stress, symmetry, and psoriasis: possible role of neuropeptides. J Am Acad Dermatol 1986;14:305-11. DOI: https://doi.org/10.1016/S0190-9622(86)70034-0
Purzycka-Bohdan D, Gleñ J, Zabłotna M, et al. Significance of interleukin-31 (IL-31) gene polymorphisms and IL-31 serum level in psoriasis in correlation with pruritus. Postepy Dermatol Alergol 2021;38:657-64. DOI: https://doi.org/10.5114/ada.2021.108926
Al-Mansoori L, Al-Jaber H, Prince MS, et al. Role of Inflammatory Cytokines, Growth Factors and Adipokines in Adipogenesis and Insulin Resistance. Inflammation 2022;45:31-44. DOI: https://doi.org/10.1007/s10753-021-01559-z
Ahmed M and Gaffen SL. IL-17 inhibits adipogenesis in part via C/EBPα, PPARγ and Krüppel-like factors. Cytokine 2013;61:898-905. DOI: https://doi.org/10.1016/j.cyto.2012.12.007
Zúñiga LA, Shen WJ, Joyce-Shaikh B, et al. IL-17 regulates adipogenesis, glucose homeostasis, and obesity. J Immunol 2010;185:6947-59. DOI: https://doi.org/10.4049/jimmunol.1001269
Shin JH, Shin DW and Noh M. Interleukin-17A inhibits adipocyte differentiation in human mesenchymal stem cells and regulates pro inflammatory responses in adipocytes. Biochem Pharmacol 2009;77:1835-44. DOI: https://doi.org/10.1016/j.bcp.2009.03.008
Leon A, Rosen JD, Hashimoto T, et al. Itching for an answer: A review of potential mechanisms of scalp itch in psoriasis. Exp Dermatol 2019;28:1397-404. DOI: https://doi.org/10.1111/exd.13947
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
